- Home
- TTGT vs LXRX Comparison
TTGT vs LXRX Comparison
Compare TTGT & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TTGT | LXRX |
|---|---|---|
| Founded | 1999 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.2M | 547.4M |
| IPO Year | 2024 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TTGT | LXRX |
|---|---|---|
| Price | $3.76 | $1.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $10.75 | $4.15 |
| AVG Volume (30 Days) | 511.3K | ★ 2.3M |
| Earning Date | 03-11-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $2.75 | $22.16 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $3.41 | $0.32 |
| 52 Week High | $15.54 | $1.83 |
Technical Indicators
Market Signals| Indicator | TTGT | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.11 | 50.52 |
| Support Level | $3.42 | $1.08 |
| Resistance Level | $5.88 | $1.65 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 23.90 | 30.88 |
Price Performance
Historical ComparisonAbout TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.